Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients With Treatment-Resistant Depression

Brain, Behavior, and Immunity - United States
doi 10.1016/j.bbi.2013.04.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Visceral Leishmaniasis in Mice Devoid of Tumor Necrosis Factor and Response to Treatment

Infection and Immunity
ParasitologyInfectious DiseasesImmunologyMicrobiology
2000English

Successful Treatment With Infliximab of a Patient With Tumor Necrosis Factor-Associated Periodic Syndrome (TRAPS) Who Failed to Respond to Etanercept

Journal of Rheumatology
RheumatologyAllergyImmunology
2010English

Tumor Necrosis Factor Α Antagonists in the Treatment of the Patients With Rheumatoid Arthritis

Reumatologia
RheumatologyAllergyImmunology
2012English

Infliximab (Anti–Tumor Necrosis Factor Α Antibody)

Archives of Dermatology
2001English

DNA Cytometric and Histologic Findings in Mouse Tumors (BP and S 180) With Different Response to Treatment With Tumor Necrosis Factor

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1990English

Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-Resistant by Treatment With Tumor Necrosis Factor-Α

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2003English

Effect of Interleukin-1 on Lipid Metabolism in the Rat. Similarities to and Differences From Tumor Necrosis Factor

Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
1991English

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

Predictors of Treatment Initiation With Tumor Necrosis Factor-Α Inhibitors in Patients With Rheumatoid Arthritis

Journal of Managed Care Pharmacy
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy